Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr:79:102196.
doi: 10.1016/j.pupt.2023.102196. Epub 2023 Jan 20.

Pulmonary drug delivery for acute respiratory distress syndrome

Qinqin Fei  1 , Ian Bentley  2 , Samir N Ghadiali  3 , Joshua A Englert  4
Affiliations
Review

Pulmonary drug delivery for acute respiratory distress syndrome

Qinqin Fei et al. Pulm Pharmacol Ther. 2023 Apr.

Abstract

The acute respiratory distress syndrome (ARDS) is a life-threatening condition that causes respiratory failure. Despite numerous clinical trials, there are no molecularly targeted pharmacologic therapies to prevent or treat ARDS. Drug delivery during ARDS is challenging due to the heterogenous nature of lung injury and occlusion of lung units by edema fluid and inflammation. Pulmonary drug delivery during ARDS offers several potential advantages including limiting the off-target and off-organ effects and directly targeting the damaged and inflamed lung regions. In this review we summarize recent ARDS clinical trials using both systemic and pulmonary drug delivery. We then discuss the advantages of pulmonary drug delivery and potential challenges to its implementation. Finally, we discuss the use of nanoparticle drug delivery and surfactant-based drug carriers as potential strategies for delivering therapeutics to the injured lung in ARDS.

Keywords: Acute respiratory distress syndrome (ARDS); Inhalation devices; Nanoparticles.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic representation of polymeric nanoparticle, polymeric micelle, liposome, and solid lipid nanoparticle. Created with BioRender.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Force A.D.T., et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–2533. - PubMed
    1. Matthay M.A., et al. Acute respiratory distress syndrome. Nat. Rev. Dis. Prim. 2019;5(1):18. - PMC - PubMed
    1. Imai Y., et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133(2):235–249. - PMC - PubMed
    1. Matthay M.A., Zimmerman G.A. Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am. J. Respir. Cell Mol. Biol. 2005;33(4):319–327. - PMC - PubMed
    1. Huppert L.A., Matthay M.A., Ware L.B. Pathogenesis of acute respiratory distress syndrome. Semin. Respir. Crit. Care Med. 2019;40(1):31–39. - PMC - PubMed

Publication types